Low‑intensity ultrasound enhances the antitumor effects of doxorubicin on hepatocellular carcinoma cells through the ROS‑miR‑21‑PTEN axis

Xia,Chunhua; Zeng,Huabei; Zheng,Yanfen

doi:10.3892/mmr.2020.10936

Low‑intensity ultrasound enhances the antitumor effects of doxorubicin on hepatocellular carcinoma cells through the ROS‑miR‑21‑PTEN axis

Authors:
- Chunhua Xia
- Huabei Zeng
- Yanfen Zheng
View Affiliations

Affiliations: Department of Ultrasound, Suqian Obstetrics and Gynecology Hospital, Suqian, Jiangsu 223800, P.R. China, Department of Ultrasound, School of Imaging of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia 014060, P.R. China
Published online on: January 13, 2020 https://doi.org/10.3892/mmr.2020.10936
Pages: 989-998
Copyright: © Xia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a type of liver cancer and is a leading cause of cancer‑associated mortality. In China, ~466,000 patients are diagnosed with HCC and it is responsible for ~422,000 cases of mortality each year. Surgery is the most effective treatment available; however it is only suitable for patients with early‑stage HCC. Chemotherapy has been confirmed as a necessary treatment for patients with advanced HCC, although drug resistance may limit its clinical outcome. Low intensity ultrasound (LIUS) represents a novel therapeutic approach to treat patients with HCC; however, its underlying molecular mechanism remains unclear. In the present study, cell viability, apoptosis and reactive oxygen species (ROS) generation were determined via Cell Counting Kit‑8, flow cytometry and 2',7'‑dichlorofluorescein diacetate assays, respectively. The expression of miRNA in HCC cells following exposure to LIUS and doxorubicin (Dox) was analyzed using a microarray and reverse transcription‑quantitative polymerase chain reaction analysis. It was revealed treatment with LIUS in combination with Dox was able to induce apoptosis of Huh7 cells, increasing the intracellular levels of reactive oxygen species (ROS) and malondialdehyde. Glutathione peroxidase and superoxide dismutase 1 are ROS‑scavenging enzymes, which serve important roles in the oxidative balance, preventing oxidative stress. The protein expression levels of these two enzymes were significantly decreased following treatment with LIUS combined with Dox. The present results suggested that LIUS may decrease Dox resistance in HCC cells and that LIUS may be combined with chemotherapy to treat HCC. By performing microarray analysis, the expression levels of microRNA‑21 (miR‑21) were decreased following treatment with LIUS combined with Dox. Functional experiments showed that knockdown of miR‑21 enhanced the antitumor activity of Dox, whereas overexpression of miR‑21 reversed these effects. Phosphatase and tensin homolog (PTEN), a well‑known tumor suppressor, was revealed to be a direct target of miR‑21, and its translation was suppressed by miR‑21. Finally, it was determined that combined treatment of LIUS and Dox induced anticancer effects by blocking the activation of the AKT/mTOR pathway, as demonstrated by the downregulation of phosphorylated (p‑)AKT and p‑mTOR; N‑acetylcysteine, a general ROS inhibitor reversed the suppressive effects on the AKT/mTOR pathway mediated by LIUS and Dox. Collectively, the present results suggested that LIUS increased cell sensitivity to Dox via the ROS/miR‑21/PTEN pathway. Chemotherapy combined with LIUS may represent a novel effective therapeutic strategy to treat patients with advanced HCC.

View Figures

View References

1	Yii AC, Tan GL, Tan KL, Lapperre TS and Koh MS: Fixed airways obstruction among patients with severe asthma: Findings from the Singapore general hospital-severe asthma phenotype study. BMC Pulm Med. 14:1912014. View Article : Google Scholar : PubMed/NCBI
2	Lurje G, Lesurtel M and Clavien PA: Multimodal treatment strategies in patients undergoing surgery for hepatocellular carcinoma. Dig Dis. 31:112–117. 2013. View Article : Google Scholar : PubMed/NCBI
3	de Lope CR, Tremosini S, Forner A, Reig M and Bruix J: Management of HCC. J Hepatol. 56 Suppl 1:S75–S87. 2012. View Article : Google Scholar : PubMed/NCBI
4	Giordano S and Columbano A: Met as a therapeutic target in HCC: Facts and hopes. J Hepatol. 60:442–452. 2014. View Article : Google Scholar : PubMed/NCBI
5	Liu L, Chen H, Wang M, Zhao Y, Cai G, Qi X and Han G: Combination therapy of sorafenib and TACE for unresectable HCC: A systematic review and meta-analysis. PLoS One. 9:e911242014. View Article : Google Scholar : PubMed/NCBI
6	Nishida N, Kitano M, Sakurai T and Kudo M: Molecular mechanism and prediction of sorafenib chemoresistance in human hepatocellular carcinoma. Dig Dis. 33:771–779. 2015. View Article : Google Scholar : PubMed/NCBI
7	Momparler RL, Karon M, Siegel SE and Avila F: Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 36:2891–2895. 1976.PubMed/NCBI
8	Rivankar S: An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 10:853–858. 2014. View Article : Google Scholar : PubMed/NCBI
9	Xu T, Zhang J, Chen W, Pan S, Zhi X, Wen L, Zhou Y, Chen BW, Qiu J, Zhang Y, et al: ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition. Cancer Lett. 377:140–148. 2016. View Article : Google Scholar : PubMed/NCBI
10	Pan JX, Wang F and Ye LY: Doxorubicin-induced epithelial-mesenchymal transition through SEMA 4A in hepatocellular carcinoma. Biochem Biophys Res Commun. 479:610–614. 2016. View Article : Google Scholar : PubMed/NCBI
11	Zhou Y, Liang C, Xue F, Chen W, Zhi X, Feng X, Bai X and Liang T: Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation. Oncotarget. 6:10350–10365. 2015.PubMed/NCBI
12	Wood AK and Sehgal CM: A review of low-intensity ultrasound for cancer therapy. Ultrasound Med Biol. 41:905–928. 2015. View Article : Google Scholar : PubMed/NCBI
13	Lv Y, Fang M, Zheng J, Yang B, Li H, Xiuzigao Z, Song W, Chen Y and Cao W: Low-intensity ultrasound combined with 5-aminolevulinic acid administration in the treatment of human tongue squamous carcinoma. Cell Physiol Biochem. 30:321–333. 2012. View Article : Google Scholar : PubMed/NCBI
14	Fan H, Li H, Liu G, Cong W, Zhao H, Cao W and Zheng J: Doxorubicin combined with low intensity ultrasound suppresses the growth of oral squamous cell carcinoma in culture and in xenografts. J Exp Clin Cancer Res. 36:1632017. View Article : Google Scholar : PubMed/NCBI
15	Lan J, Huang Z, Han J, Shao J and Huang C: Redox regulation of microRNAs in cancer. Cancer Lett. 418:250–259. 2018. View Article : Google Scholar : PubMed/NCBI
16	Xiao Y, Yan W, Lu L, Wang Y, Lu W, Cao Y and Cai W: p38/p53/miR-200a-3p feedback loop promotes oxidative stress-mediated liver cell death. Cell Cycle. 14:1548–1558. 2015. View Article : Google Scholar : PubMed/NCBI
17	Yang H, Li TW, Zhou Y, Peng H, Liu T, Zandi E, Martínez-Chantar ML, Mato JM and Lu SC: Activation of a novel c-Myc-miR27-prohibitin 1 circuitry in cholestatic liver injury inhibits glutathione synthesis in mice. Antioxid Redox Signal. 22:259–274. 2015. View Article : Google Scholar : PubMed/NCBI
18	Jin F, Wang Y, Li M, Zhu Y, Liang H, Wang C, Wang F, Zhang CY, Zen K and Li L: MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis. 8:e25402017. View Article : Google Scholar : PubMed/NCBI
19	Zhang C, Liu X, Qiang H, Li K, Wang J, Chen D and Zhuang Y: Inhibitory effects of rosa roxburghii tratt juice on in vitro oxidative modification of low density lipoprotein and on the macrophage growth and cellular cholesteryl ester accumulation induced by oxidized low density lipoprotein. Clin Chim Acta. 313:37–43. 2001. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Hu Z, Lv G, Li Y, Li E, Li H, Zhou Q, Yang B and Cao W: Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound. J Exp Clin Cancer Res. 35:712016. View Article : Google Scholar : PubMed/NCBI
22	Pfeffer SR, Yang CH and Pfeffer LM: The role of miR-21 in cancer. Drug Dev Res. 76:270–277. 2015. View Article : Google Scholar : PubMed/NCBI
23	He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S and Sun X: MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. Oncotarget. 6:28867–28881. 2015. View Article : Google Scholar : PubMed/NCBI
24	Li ZB, Li ZZ, Li L, Chu HT and Jia M: MiR-21 and miR-183 can simultaneously target SOCS6 and modulate growth and invasion of hepatocellular carcinoma (HCC) cells. Eur Rev Med Pharmacol Sci. 19:3208–3217. 2015.PubMed/NCBI
25	Huang CS, Yu W, Cui H, Wang YJ, Zhang L, Han F and Huang T: Increased expression of miR-21 predicts poor prognosis in patients with hepatocellular carcinoma. Int J Clin Exp Pathol. 8:7234–7238. 2015.PubMed/NCBI
26	Lim HJ, Crowe P and Yang JL: Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol. 141:671–689. 2015. View Article : Google Scholar : PubMed/NCBI
27	Leslie NR and Downes CP: PTEN function: How normal cells control it and tumour cells lose it. Biochem J. 382:1–11. 2004. View Article : Google Scholar : PubMed/NCBI
28	Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li JH, Xu XM, Liu S, Chen J, Liu F, et al: Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer. 122:433–443. 2008. View Article : Google Scholar : PubMed/NCBI
29	Yang SM, Huang C, Li XF, Yu MZ, He Y and Li J: miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology. 306:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
30	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
31	Kirstein MM and Vogel A: The pathogenesis of hepatocellular carcinoma. Dig Dis. 32:545–553. 2014. View Article : Google Scholar : PubMed/NCBI
32	Rich NE, Yopp AC and Singal AG: Medical management of hepatocellular carcinoma. J Oncol Pract. 13:356–364. 2017. View Article : Google Scholar : PubMed/NCBI
33	Reig M, Darnell A, Forner A, Rimola J, Ayuso C and Bruix J: Systemic therapy for hepatocellular carcinoma: The issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis. 34:444–455. 2014. View Article : Google Scholar : PubMed/NCBI
34	Pan ST, Li ZL, He ZX, Qiu JX and Zhou SF: Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol. 43:723–737. 2016. View Article : Google Scholar : PubMed/NCBI
35	Lohitesh K, Chowdhury R and Mukherjee S: Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: An insight. Cancer Cell Int. 18:442018. View Article : Google Scholar : PubMed/NCBI
36	Draper DO: Facts and misfits in ultrasound therapy: Steps to improve your treatment outcomes. Eur J Phys Rehabil Med. 50:209–216. 2014.PubMed/NCBI
37	Wu F: High intensity focused ultrasound: A noninvasive therapy for locally advanced pancreatic cancer. World J Gastroenterol. 20:16480–16488. 2014. View Article : Google Scholar : PubMed/NCBI
38	Xia B, Zou Y, Xu Z and Lv Y: Gene expression profiling analysis of the effects of low-intensity pulsed ultrasound on induced pluripotent stem cell-derived neural crest stem cells. Biotechnol Appl Biochem. 64:927–937. 2017. View Article : Google Scholar : PubMed/NCBI
39	Duco W, Grosso V, Zaccari D and Soltermann AT: Generation of ROS mediated by mechanical waves (ultrasound) and its possible applications. Methods. 109:141–148. 2016. View Article : Google Scholar : PubMed/NCBI
40	Jang HJ, Lee JY, Lee DH, Kim WH and Hwang JH: Current and future clinical applications of high-intensity focused ultrasound (HIFU) for pancreatic cancer. Gut Liver. 4 Suppl 1:S57–S61. 2010. View Article : Google Scholar : PubMed/NCBI
41	Shi J, Chen Z, Wang B, Wang L, Lu T and Zhang Z: Reactive oxygen species-manipulated drug release from a smart envelope-type mesoporous titanium nanovehicle for tumor sonodynamic-chemotherapy. ACS Appl Mater Interfaces. 7:28554–28565. 2015. View Article : Google Scholar : PubMed/NCBI
42	Ma X, Conklin DJ, Li F, Dai Z, Hua X, Li Y, Xu-Monette ZY, Young KH, Xiong W, Wysoczynski M, et al: The oncogenic microRNA miR-21 promotes regulated necrosis in mice. Nat Commun. 6:71512015. View Article : Google Scholar : PubMed/NCBI
43	Melnik BC: MiR-21: An environmental driver of malignant melanoma? J Transl Med. 13:2022015. View Article : Google Scholar : PubMed/NCBI
44	Sekar D, Krishnan R, Thirugnanasambantham K, Rajasekaran B, Islam VI and Sekar P: Significance of microRNA 21 in gastric cancer. Clin Res Hepatol Gastroenterol. 40:538–545. 2016. View Article : Google Scholar : PubMed/NCBI
45	Worby CA and Dixon JE: Pten. Annu Rev Biochem. 83:641–669. 2014. View Article : Google Scholar : PubMed/NCBI